Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
MAGNEVIST is an injectable small-molecule contrast agent approved by the FDA in 2000 for diagnostic imaging applications. The product is administered via injection to enhance visualization in medical imaging procedures. Specific indications and mechanism of action are not publicly detailed in available data.
Product is in late-stage lifecycle with moderate competitive pressure (30% intensity), suggesting team focus is on lifecycle management and defensive positioning rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Gadobutrol Magnevist-controlled Body Study
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Magnevist Post-marketing Surveillance in Japan
Multihance Versus Magnevist in Breast MRI
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography
Worked on MAGNEVIST at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on MAGNEVIST offers limited external career momentum given the approaching loss of exclusivity and zero linked job postings. This is a legacy product requiring defensive commercial strategy rather than growth-oriented roles, making it a stabilizing but not career-accelerating assignment.